Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Current Assets (2016 - 2025)

Northwest Biotherapeutics' Current Assets history spans 16 years, with the latest figure at $5.5 million for Q4 2025.

  • Quarterly results put Current Assets at $5.5 million for Q4 2025, up 35.82% from a year ago — trailing twelve months through Dec 2025 was $5.5 million (up 35.82% YoY), and the annual figure for FY2025 was $5.5 million, up 35.82%.
  • Current Assets for Q4 2025 was $5.5 million at Northwest Biotherapeutics, down from $7.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $17.3 million in Q4 2021 to a low of $4.1 million in Q4 2024.
  • The 5-year median for Current Assets is $6.7 million (2021), against an average of $7.6 million.
  • The sharpest move saw Current Assets soared 266.32% in 2021, then crashed 56.23% in 2023.
  • Year by year, Current Assets stood at $17.3 million in 2021, then tumbled by 45.49% to $9.4 million in 2022, then crashed by 56.23% to $4.1 million in 2023, then fell by 1.53% to $4.1 million in 2024, then soared by 35.82% to $5.5 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $5.5 million, $7.2 million, and $6.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.